Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289342239> ?p ?o ?g. }
- W4289342239 endingPage "1027" @default.
- W4289342239 startingPage "1027" @default.
- W4289342239 abstract "Background and objectives: Pancreatic adenocarcinoma represents one of the common malignancies with a relatively poor prognosis. However, early detection of this type of cancer may prove to be curable. Recent advancements in the radiological techniques might represent a hope for the early diagnosis and prediction of prognosis of pancreatic adenocarcinoma. This study aimed to assess the prognostic value of the primary tumor volumetric parameters obtained from FDG PET/CT first stage for the overall survival (OS) and progression-free survival (PFS) of patients with pancreatic adenocarcinoma and to explore the possible correlation between serum matrix metalloproteinase-2 (MMP-2) and the patients’ characteristics. Methods: Fifty patients with pancreatic adenocarcinoma were subjected to FDG PET/CT scan. The SUVpeak, SUVmax, and the metabolic tumor volume (MTV) were determined, as well as the SUVmean of the liver. Moreover, serum levels of MMP-2 were assessed. Follow-up of the patients was carried out for sixty months with determination of PFS and OS. Results: Peak SUV ≥ 3.9 was significantly correlated with the primary pancreatic lesions’ mean total glycolytic activity of >92 g, and MTV and was directly correlated with mortality. There was a positive correlation between peak SUV ≥ 3.9 and 50% SUVmax threshold > 82. Moreover, there was significant correlation between the total glycolytic activity and the studied clinicopathologic factors, except the age and sex of the patients and ECOG performance status. In addition, FDG uptake and the tumor glycolytic activity were substantially linked with a shorter PFS. Similarly, a strong correlation was found between MTV and PFS. Serum MMP-2 levels showed a significant relationship with the performance status, tumor stage, SUVmax threshold, and the glycolytic activity. Conclusions: Peak SUV, main lesion SUVmax, serum MMP-2, and the tumor glycolytic activity are good predictors of PFS of patients with pancreatic adenocarcinoma." @default.
- W4289342239 created "2022-08-02" @default.
- W4289342239 creator A5008255579 @default.
- W4289342239 creator A5021433038 @default.
- W4289342239 creator A5024357259 @default.
- W4289342239 creator A5027136632 @default.
- W4289342239 creator A5048359168 @default.
- W4289342239 creator A5087771737 @default.
- W4289342239 creator A5088829801 @default.
- W4289342239 date "2022-08-01" @default.
- W4289342239 modified "2023-09-25" @default.
- W4289342239 title "The Significance of FDG PET/CT–Derived Parameters in Determining Prognosis of Cases with Pancreatic Adenocarcinoma: A Prospective Study" @default.
- W4289342239 cites W1986249544 @default.
- W4289342239 cites W1987473753 @default.
- W4289342239 cites W2018261701 @default.
- W4289342239 cites W2023570529 @default.
- W4289342239 cites W2024885492 @default.
- W4289342239 cites W2030344030 @default.
- W4289342239 cites W2054864984 @default.
- W4289342239 cites W2071121228 @default.
- W4289342239 cites W2073017415 @default.
- W4289342239 cites W2127820101 @default.
- W4289342239 cites W2136155784 @default.
- W4289342239 cites W2137915429 @default.
- W4289342239 cites W2143747234 @default.
- W4289342239 cites W2149878608 @default.
- W4289342239 cites W2171719821 @default.
- W4289342239 cites W2227146534 @default.
- W4289342239 cites W2260079857 @default.
- W4289342239 cites W2297899744 @default.
- W4289342239 cites W2316996772 @default.
- W4289342239 cites W2352744595 @default.
- W4289342239 cites W2468420207 @default.
- W4289342239 cites W2571466875 @default.
- W4289342239 cites W2768021087 @default.
- W4289342239 cites W2789316983 @default.
- W4289342239 cites W2889646458 @default.
- W4289342239 cites W2909938780 @default.
- W4289342239 cites W2917919815 @default.
- W4289342239 cites W3092007298 @default.
- W4289342239 cites W3094285617 @default.
- W4289342239 cites W3101964155 @default.
- W4289342239 cites W3109419327 @default.
- W4289342239 cites W3127564697 @default.
- W4289342239 cites W3137936827 @default.
- W4289342239 cites W3150537508 @default.
- W4289342239 cites W3165149381 @default.
- W4289342239 cites W3174489108 @default.
- W4289342239 cites W3200216062 @default.
- W4289342239 cites W3212093805 @default.
- W4289342239 cites W4200344606 @default.
- W4289342239 cites W4206059240 @default.
- W4289342239 cites W4226437693 @default.
- W4289342239 cites W434643510 @default.
- W4289342239 doi "https://doi.org/10.3390/medicina58081027" @default.
- W4289342239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36013494" @default.
- W4289342239 hasPublicationYear "2022" @default.
- W4289342239 type Work @default.
- W4289342239 citedByCount "0" @default.
- W4289342239 crossrefType "journal-article" @default.
- W4289342239 hasAuthorship W4289342239A5008255579 @default.
- W4289342239 hasAuthorship W4289342239A5021433038 @default.
- W4289342239 hasAuthorship W4289342239A5024357259 @default.
- W4289342239 hasAuthorship W4289342239A5027136632 @default.
- W4289342239 hasAuthorship W4289342239A5048359168 @default.
- W4289342239 hasAuthorship W4289342239A5087771737 @default.
- W4289342239 hasAuthorship W4289342239A5088829801 @default.
- W4289342239 hasBestOaLocation W42893422391 @default.
- W4289342239 hasConcept C117220453 @default.
- W4289342239 hasConcept C121608353 @default.
- W4289342239 hasConcept C126322002 @default.
- W4289342239 hasConcept C126838900 @default.
- W4289342239 hasConcept C143998085 @default.
- W4289342239 hasConcept C146357865 @default.
- W4289342239 hasConcept C151730666 @default.
- W4289342239 hasConcept C199374082 @default.
- W4289342239 hasConcept C2524010 @default.
- W4289342239 hasConcept C2775842073 @default.
- W4289342239 hasConcept C2780210213 @default.
- W4289342239 hasConcept C2781182431 @default.
- W4289342239 hasConcept C33923547 @default.
- W4289342239 hasConcept C71924100 @default.
- W4289342239 hasConcept C86803240 @default.
- W4289342239 hasConcept C90924648 @default.
- W4289342239 hasConceptScore W4289342239C117220453 @default.
- W4289342239 hasConceptScore W4289342239C121608353 @default.
- W4289342239 hasConceptScore W4289342239C126322002 @default.
- W4289342239 hasConceptScore W4289342239C126838900 @default.
- W4289342239 hasConceptScore W4289342239C143998085 @default.
- W4289342239 hasConceptScore W4289342239C146357865 @default.
- W4289342239 hasConceptScore W4289342239C151730666 @default.
- W4289342239 hasConceptScore W4289342239C199374082 @default.
- W4289342239 hasConceptScore W4289342239C2524010 @default.
- W4289342239 hasConceptScore W4289342239C2775842073 @default.
- W4289342239 hasConceptScore W4289342239C2780210213 @default.
- W4289342239 hasConceptScore W4289342239C2781182431 @default.
- W4289342239 hasConceptScore W4289342239C33923547 @default.
- W4289342239 hasConceptScore W4289342239C71924100 @default.